相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates
Guolan Lu et al.
NATURE COMMUNICATIONS (2020)
A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Yao Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3K gamma to Promote Pancreatic Cancer Metastasis
Xiaofeng Wang et al.
CANCER RESEARCH (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy
Dominik Schmiedel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
Yasuko Tada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl et al.
IMMUNOBIOLOGY (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer
Keehoon Jung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases
Jiemiao Hu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue
Hormas Ghadially et al.
BRITISH JOURNAL OF CANCER (2017)
A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma
Tong Wang et al.
CANCER LETTERS (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer
Wei Xei et al.
Oncotarget (2016)
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment
Eric T. Alexander et al.
ONCOTARGET (2016)
Targeting angiogenesis in gastrointestinal tumors: current challenges
Amara G. Nandikolla et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells
Daniela Schilling et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells
Stephan Kloess et al.
ONCOIMMUNOLOGY (2015)
NKG2D signaling in cancer immunosurveillance
Alejandro Lopez-Soto et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth
Zi-Xue Xuan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand
Kyohei Nakamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell-Tumor Cell Interactions
Jacques Deguine et al.
JOURNAL OF IMMUNOLOGY (2012)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Kazuki N. Sugahara et al.
SCIENCE (2010)
Phytoglycoprotein inhibits interleukin-1β and interleukin-6 via p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated RAW 264.7 cells
Sei-Jung Lee et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
NK cells and cancer immunosurveillance
I. Waldhauer et al.
ONCOGENE (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Vascular endothelial growth factor family of ligands and receptors: Review
Zaher K. Otrock et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
A Sica et al.
EUROPEAN JOURNAL OF CANCER (2006)
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen
J Moffat et al.
CELL (2006)
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
M Shibuya et al.
EXPERIMENTAL CELL RESEARCH (2006)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
分享论文
